Simvastatin inhibits 20-Hydroxyeicosatetraenoic acid formation: docking and in vitro assay

辛伐他汀抑制20-羟基二十碳四烯酸的形成:分子对接和体外试验

阅读:1

Abstract

INTRODUCTION: 20-Hydroxyeicosatetraenoic acid (20-HETE), a metabolite of arachidonic acid catalyzed mainly by cytochrome P450 (CYP) enzymes CYP4A11 and CYP4F2, plays a role in cardiovascular homeostasis. Elevated levels of 20-HETE are associated with hypertension. Accordingly, 20-HETE is a potential target for therapeutic interventions. AIMS: This study aimed to evaluate the effects of commonly prescribed statins simvastatin, atorvastatin, and rosuvastatin on 20-HETE formation in human liver microsomes and to conduct molecular docking simulations with CYP4A11 and CYP4F2. METHODS: Human liver microsomes were used to assess 20-HETE formation inhibition. Molecular docking simulations were performed using predicted structures of CYP4A11, CYP4F2, and CYP4F3B. The binding affinity of simvastatin was evaluated based on lowest energy of binding (LEB) values, and interactions with the heme group were analyzed. RESULTS: In vitro assay showed that simvastatin, but not other tested statins, inhibited the formation of 20-HETE in the human liver microsome with IC(50) value of 10 µM and in a competitive mechanism as shown in the kinetics of the Lineweaver-Burk plot. Using in silico tools, simvastatin showed a significant inhibitory effect on CYP4A11, CYP4F2, and CYP4F3B with LEB values of -11.06, -9.93, and − 11.55 kcal/mol, respectively, indicating a stronger interaction compared to the known inhibitor HET0016. Simvastatin interacted predominantly with multiple hydrogen bonds and with the heme group of CYP4A11. CONCLUSIONS: Simvastatin effectively inhibits the formation of 20-HETE most probably through interaction with CYP4A11, CYP4F2, and CYP4F3B, suggesting its potential as a therapeutic agent for managing conditions associated with elevated 20-HETE levels. Further clinical investigations are needed to explore its implications in cardiovascular diseases associated with elevated 20-HETE levels. CLINICAL TRIAL NUMBER: Not applicable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40360-025-00976-2.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。